Autolus Therapeutics plc ADR(AUTL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:37 PM ET (Korea 10/31 07:37)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.05 | Insider Own | 9.63% | Shs Outstand | 266.2M | Perf Week | -1.3% |
| Market Cap | 0.40B | Forward P/E | - | EPS next Y | 19.49% | Insider Trans | -0.03% | Shs Float | 240.5M | Perf Month | -17.84% |
| Enterprise Value | 0.57B | PEG | - | EPS next Q | -0.16 | Inst Own | 45.87% | Short Float | 3.77% | Perf Quarter | -16.48% |
| Income | -0.28B | P/S | 3.45 | EPS this Y | 27.47% | Inst Trans | -2.32% | Short Ratio | 4.01 | Perf Half Y | 3.4% |
| Sales | 0.12B | P/B | 7.21 | EPS next 5Y | 25.87% | ROA | -46.04% | Short Interest | 9.07M | Perf YTD | -23.62% |
| Book/sh | 0.21 | P/C | 1.99 | EPS past 3/5Y | 11.57% 17.04% | ROE | -132.68% | 52W High | -41.09% ($2.58) | Perf Year | 0.66% |
| Cash/sh | 0.76 | P/FCF | - | Sales past 3/5Y | 130.25% 215.43% | ROIC | -65.92% | 52W Low | 29.36% ($1.17) | Perf 3Y | -44.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -21.91% | Gross Margin | 12.87% | Volatility(W/M) | 5.41% 5.71% | Perf 5Y | -72.76% |
| Dividend TTM | - | EV/Sales | 4.85 | Sales Y/Y TTM | 287.93% | Oper. Margin | -210.52% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.36 | EPS Q/Q | 19.25% | Profit Margin | -238.34% | RSI (14) | 36.61 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.85 | Sales Q/Q | 116.09% | SMA20 | -8.38% ($1.66) | Beta | 2.29 | Target Price | $8.44 |
| Payout | - | Debt/Eq | 4.91 | Earnings | 2026/11/10 | SMA50 | -20.29% ($1.91) | Rel Volume | 0.74 | Prev Close | $1.58 |
| Employees | 752 | LT Debt/Eq | 4.66 | EPS/Sales Surpr. | 22.8% 18.49% | SMA200 | -8.77% ($1.67) | Avg Volume(3M) | 2.26M | Price | $1.52 |
| IPO | 2018/6/22 | Option/Short | Yes/Yes | Trades | 4899 | Volume | 1,675,296 | Change | -3.8% |
🧬 Autolus Therapeutics is a UK-based biotech company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies, trading on Nasdaq under the ticker AUTL. The company has entered the commercialization phase in the field of precision cell therapies targeting relapsed and refractory hematologic cancers, leveraging its proprietary programming technology, and is expanding its indications into hematologic malignancies and autoimmune diseases.
Over the past 1 year, on the lower side
41% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
Next earnings report: November 10
10 days to go.
AUTL has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $345. Peers typically go for $1,268.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -72.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #236 of 597 in the industry
Based on market cap of $405M.
EDIT#233 Editas Medicine Inc $410M PER - 
ASMB#234 Assembly Biosciences Inc $410M PER - 
ALLO#235 Allogene Therapeutics Inc $408M PER - AUTL#236 Autolus Therapeutics plc ADR $405M PER - 
ALT#237 Altimmune Inc $397M PER - 
FAQ
What kind of company is AUTL?
AUTL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AUTL?
The market cap of AUTL is approximately $405M, ranking 3,318 within its sector.
What is the 52-week high and low for AUTL?
AUTL has recorded a 52-week high of $2.58 and a low of $1.17.
